PCAB Accreditation

Synergy proudly announces its achievement of accreditation from the Pharmacy Compounding Accreditation Board (PCAB), thus joining an elite group of pharmacies nationwide with this distinction. Recognition is provided to Synergy for the pharmacy’s commitment to meeting and/or exceeding the highest quality and safety standards in its profession.


Achieving accreditation is a process where healthcare organizations demonstrate compliance with national standards. PCAB accreditation reflects an organization’s dedication and commitment to meeting standards that facilitate a higher level of performance and patient care.

“We are honored by this accreditation. It confirms our dedication to protecting our patients by practicing safe, high-quality personalized solutions that address patient’s medical needs,” said Michael Palso, Synergy’s COO. “We believe this will only further strengthen the bonds of trust between our pharmacy, patients, and the healthcare providers who rely on us for these specialized medications.”

Established in 2007, PCAB was founded by eight of the nation’s leading pharmacy organizations to create voluntary quality accreditation designation for the compounding industry. The organization promotes, develops, and maintains principles, policies and standards for improving the quality of pharmacy compounding nationwide.

Fighting the Opioid Epidemic

Fighting the Opioid Epidemic

With 78 deaths in the United States each day from opioid overdose and a 300% increase in associated prescription sales since 1999, opiate addiction has reached a crisis level.

In August 2016, the U.S. Surgeon General, Dr. Vivek Murthy, mailed 2.3 million letters to physicians and medical professionals asking for their help to decrease prescription usage of opioids, as he believes that “clinicians have the unique power to end this epidemic.” This campaign, titled “Turn the Tide Rx”, has launched to focus on clinicians in three main areas:

1) Education on the addictiveness of painkillers and how to treat pain safely and effectively;
2) Screening patients for opioid abuse disorder and connecting them with evidence-based treatments;
3) Changing the public view of addiction to be seen as a chronic illness and not a moral issue.


Compounding for pain management offers a unique solution to this opioid epidemic. Clinical research backs up this view as well. In 2013, Patient Outcomes Analytics completed a nationwide survey of 3,600 chronic pain sufferers to assess patients’ experience with topical prescription pain creams in relation to their impact on oral pain medications. Findings published in the Journal of Medical Care, revealed that more than 83 percent of the participants reported a significant decrease in their pain. In addition, a reduction in oral pain medications was reported in 38 percent of these patients.

Prescription topical pain compounds offer advantages over oral opioid medications. These benefits range from a lowered total systemic daily dose for patients to achieve pain relief, site-specific drug delivery, and avoidance of first-pass metabolism. In addition, added benefits include overall decrease in major drug interactions, risk of addiction, and gastrointestinal, renal, or hepatic exposure. These prescription topical pain products work by attacking the pain’s dual pathways directly through the skin at the source of the localized pain.

At Synergy Health Services, we support the U.S. Surgeon General’s goal to curb the overuse of prescription opioids. We honor this pledge as a non-narcotic compounding pharmacy by offering topical pain therapies that are non-addictive and non-abusive.

As an accredited pharmacy, we work directly with physicians and clinicians to offer pain solutions that are customized to meet their patients’ healthcare needs. Despite pain being arthritic, nociceptive, neuropathic, chronic or acute in nature, there are topical therapies available to help reduce patients’ pain level and opioid dosage, as well as the possible weaning of narcotics.

We commend the U.S. Surgeon General’s call to action for the medical community to reduce opioid prescribing practices. Patient-specific, compounded pain medications, from an accredited compounding pharmacy, is what we can offer to support his efforts for alternative treatments. Together, we will take a stand to end this urgent health crisis on opioid dependence to better the community we serve.

Distracted Driving – How big is the problem?

Each day in the United States, more than 9 people are killed and more than 1,060 people are injured in crashes that are reported to involve a distracted driver. Distracted driving is driving while doing another activity that takes your attention away from driving. Distracted driving can increase the chance of a motor vehicle crash.

There are three main types of distraction:

Visual: taking your eyes off the road

Manual: taking your hands off the wheel

Cognitive: taking your mind off of driving

Distracted driving activities include things like using a cell phone, texting, and eating. Using in-vehicle technologies (such as navigation systems) can also be sources of distraction. While any of these distractions can endanger the driver and others, texting while driving is especially dangerous because it combines all three types of distraction.

Difference In Pill Color May Affect Patient’s Adherence

Hand Full of PillsGeneric medications are biologically identical to their brand-name counterparts, however, their physical traits, like shape or color, usually differ. Patients who take generic drugs that differ in color are 50 percent more likely to stop the intake of the drug, producing possible negative reactions, according to a new study by Brigham and Women’s Hospital (BWH).

The findings were published in the Archives of Internal Medicine. The case-control study analyzed patients taking antiepileptic drugs and looked at the probability that patients who did not refill their prescriptions had been taking medication with a different shape or color from earlier prescriptions.

Rocker Sole shoes, NO more effective

RockerSoleShoes3New research published in forthcoming issue of the journal Spine shows that ‘rocker sole’ shoes, widely used worldwide to help treat people with lower back pain are no more effective than traditional training shoes (trainers) and that trainers appear to be more beneficial for those with back pain aggravated by standing or walking.

This research provides the first robust evidence showing that, contrary to claims made by manufacturers, rocker sole shoes do not help reduce lower back pain.